Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Diluted Average) (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $82.1 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 14.01% year-over-year to $82.1 million; the TTM value through Mar 2026 reached $82.1 million, up 14.01%, while the annual FY2025 figure was $72.9 million, 15.42% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $82.1 million in Q1 2026 for Phathom Pharmaceuticals, up from $72.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $82.1 million in Q1 2026 and bottomed at $38.0 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $56.6 million, with a median of $58.4 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Diluted Average) surged 46.27% in 2023 and then rose 6.62% in 2024.
  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $39.1 million in 2022, then soared by 31.11% to $51.3 million in 2023, then grew by 23.18% to $63.2 million in 2024, then grew by 15.42% to $72.9 million in 2025, then increased by 12.52% to $82.1 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $82.1 million, $72.9 million, and $72.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.